Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
Syntara (ASX:SNT) has 0.24% of its shares on issue reported as short positions as of 7 July 2026, or about 4,806,305 shares. Over the past 30 days that figure has risen 0.24 percentage points, and over 90 days it has risen 0.11 percentage points. SNT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Syntara (SNT) company profile
Profile, insiders and operations
Company
AI-generated research profile of Syntara
SNT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links